In recent years, several reversible and irreversible small-molecule menin inhibitors (such as MI-503, M-525, MI-136 or MI-2) were reported and used to explore the role of menin in different cancer indications [9,10,13,19,20,21,22,23,24,25]. The gene discussed is MEN1; the disease is cancer.